Anti-viral effect of PC786 on RSV infection in HSCT recipients
Research type
Research Study
Full title
A double blind, placebo-controlled study to assess the antiviral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult hematopoietic stem cell transplant recipients
IRAS ID
248988
Contact name
Amit Patel
Contact email
Sponsor organisation
Pulmocide Ltd
Eudract number
2018-001667-24
ISRCTN Number
ISRCTN00000000
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 6 months, 16 days
Research summary
The purpose of this study is to test the effects of an experimental drug PC786 for people infected with Respiratory Syncytial Virus (RSV). RSV is one of the viruses which cause the 'common cold'. PC786 may be useful in treating patients infected with RSV as it works by interfering with the way the virus multiplies. PC786 is an inhaled medicine and should have a low risk of systemic side effects, as only small amount of the medicine will get to bloodstream. The study will take place at multiple sites in UK with approximately 30 participants and the maximum study duration is about 4 weeks. The study has 3 stages: Screening (up to 2 days), Treatment period (3 days) and Follow-up (about 25 days).
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
18/EM/0228
Date of REC Opinion
21 Aug 2018
REC opinion
Further Information Favourable Opinion